



Transcript

SA HIV Clinicians Society Newsletter

August 2011

INDEX:

Society Contact Details.....	1	Important Information on CPD Points	6
Bursaries to AWAAC.....	1	Training Courses	7
Optimal Time to Start ART in Patients with TB	2	Conferences 2011.....	9
RCT of Influenza Vaccination in HIV.....	3	Resources and Services Available	10
Society Publications.....	3	The Society Guidelines	11
Branch Meetings Dates 2011.....	4	Recommended Reading	11
Branch Meeting Presentations.....	6	Internet-based Discussion Groups.....	12
Emerging Issues Meetings – Johannesburg.....	6	The latest Antiretroviral (ART) SEP Prices	12

Society Contact Details

Head Office (for general queries):

Tel: + 27 (0)11 341 0162; Fax: +27 (0)11 341 0161

Mpho Maledimo, Office Administrator: mpho@sahivsoc.org

Laurie Schowalter, Technical Advisor: laurie@sahivsoc.org

Fatima Shaik, General Manager: fatimas@sahivsoc.org

Nelouise Geyer: Editor, *HIV Nursing Matters*:
nelouise@sahivsoc.org

Database Office (for membership/payment queries):

Tel: 071 868 0789; Fax: 086 682 2880

Jean Solan, Bookkeeper: jeansolan@global.co.za

Kerry Solan, Database Assistant: kerrysolan@global.co.za

Pat Solan, Database Manager: patsolan@global.co.za

Website: www.sahivsoc.org

Bursaries for Nurses to Attend AWAAC

The Society is offering a **limited number** of bursaries to its nurse and midwife members to attend the [5th Annual Workshop on Advanced Clinical Care](#), scheduled for 6-7 October in Durban. The bursary will cover the conference registration fee, and each bursary holder will receive a reimbursement of R1 800 towards their travel and accommodation costs (terms and conditions apply). The reimbursement will be paid after the conference, and bursary holders will be required to sign in each day of the conference in order to be eligible for the reimbursement.

The Society will organize the registration of successful applicants and pay the registration fee directly to the conference organisers. If you have already registered for the conference, please inform us of this in your application. Please note that the Society will not arrange for or pay for travel and/or accommodation – this is the responsibility of the individual.

Minimum requirements:

- Working in a setting where ARVs are available (as ART or PMTCT)
- Personally involved in clinical care of patients at least 3 days per week

Note: only Society nurse members whose annual membership fees have been paid in full will be considered.

Application process:

Please submit the following to fax: 011 341 0161 or e-mail: sahivsoc@sahivsoc.org

1. A brief outline of involvement in the field of HIV, including your current job responsibilities. Please include your current job title.
2. A letter of **support for leave** to attend the conference from your manager/supervisor.
3. A letter detailing a commitment and plan to provide information gained at the conference to colleagues.
4. Contact information, including a telephone number, cell number, e-mail address and fax number. Please include your physical address (residential) and work address.

Closing date: 31 August 2011

Please note: Bursary recipients who fail to attend the conference after the Society has paid their registration fees will be required to refund the Society for all expenses incurred.

For more information about AWAAC, visit www.mccord.co.za or contact Karen Moodley at Karen@mccord.co.za.

When is the Optimal Time to Start ART in Patients with TB? Recent Findings

Prof Graeme Meintjes

In many patients with HIV infection in South Africa the HIV diagnosis is only made after they present to the health care services with active TB and a low CD4 count. The first priority in such patients is to diagnose and treat the TB. The question then is when to start ART. Because of the complexities of ART initiation in patients with TB (eg. IRIS, shared drug toxicities, drug interactions and pill burden) many clinicians choose to defer ART. However, in patients with low CD4 counts this means that patients remain at high risk of HIV disease progression with associated mortality. To answer the question of when the optimal time to start ART in such patients is, a number of recent randomized strategy trials have compared different timing of ART initiation during TB treatment. These studies are discussed here followed by recommendations based on this evidence.

The CAMELIA study [1] conducted in Cambodia among patients with smear positive TB and $CD4 \leq 200$ cells/microlitre compared starting ART 2 weeks versus 8 weeks after starting TB treatment. Patients in this trial had very advanced HIV with median $CD4 = 25$ cells/microlitre and $BMI = 17$. There was a 34% reduction in mortality in those who started at 2 weeks.

The ACTG 5221 STRIDE study [2] was a multi-country study that enrolled patients with confirmed or suspected TB and had a $CD4 < 250$ cells/microlitre. ART was started 2 weeks after TB treatment in the one arm and 8-12 weeks in the other. There was no difference in the combined endpoint of AIDS progression and death between the two arms. However, in a subanalysis of only those with $CD4 \leq 50$ cells/microlitre AIDS progression and death was reduced by 42% among those who started at 2 weeks.

Similar findings were demonstrated in the SAPiT study [3] conducted in Durban. This study enrolled patients with smear-positive PTB and $CD4 < 500$ cells/microlitre. The most recent report from this study, presented at the 18th Conference on Retroviruses and Opportunistic Infections, compared outcomes in the two integrated arms of the study: one arm started ART within 4 weeks of starting TB treatment and the other within 4 weeks of the completion of intensive phase of TB treatment. There was no difference in the combined endpoint of AIDS progression or death comparing the two arms, but again in a subanalysis of those with $CD4 < 50$ cells/microlitre, earlier ART (at a median of 8 days) reduced AIDS progression or death by 68% (marginally significant, $p=0.06$).

In all three of these studies, the incidence of paradoxical TB-IRIS was approximately 2 to 3 fold higher among those starting ART in the earlier arm. Despite this, however, in patients with $CD4 < 50$ these studies demonstrated that the survival benefit of earlier ART outweighs the potential risk that earlier ART may cause excess TB-IRIS related deaths.

Finally, in a study of ART timing in patients with TB meningitis conducted in Vietnam [4] there was no difference in survival among patients starting ART immediately or deferring 2 months. Mortality at 9 months was around 60% in both arms. Patients in this study were treated with adjunctive high dose dexamethasone for the first 6-8 weeks of TB treatment. Grade 4 adverse events were encountered more frequently by patients who started immediately.

In conclusion, these studies demonstrate that TB patients with a $CD4 < 50$ cells/microlitre benefit from starting ART within 2 weeks of starting TB treatment with one study showing this reduced mortality and two demonstrating a reduction in AIDS progression/death among these patients. These patients (with $CD4 < 50$ cells/microlitre) should be prioritised for rapid medical work-up and counseling to allow them to start ART within 2 weeks of TB treatment. In patients with a $CD4$ close to 50 cells/microlitre or those with other stage 4 defining illnesses it may also be prudent to start after 2 weeks of TB treatment. Among those with higher $CD4$ counts deferring ART up to 2 months may reduce the risk of TB-IRIS without compromising outcome. In TB meningitis mortality is extremely high and unaffected by the exact timing of ART within the first 2 months of TB treatment and deferring ART a few weeks may reduce risk of severe adverse events.

References

- 1) Blanc et al, 18th IAS Conference 2010, Abstract THLBB106
- 2) Havlir et al, 18th Conference on Retroviruses and Opportunistic Infections, Abstract 38
- 3) Abdool Karim et al, 18th Conference on Retroviruses and Opportunistic Infections, Abstract 39LB
- 4) Torok, 41st Union World Conference on Lung Health 2010

*This article is reprinted with permission from the Aid for Aids (AfA) Healthcare Professional Newsletter, June 2011: Issue 29. All AfA Healthcare Professional Newsletters are available online at <http://www.aidforaids.co.za>. Past issues can also be downloaded on the Society's website, www.sahivsoc.org, under the **publications** tab.*

African RCT of Influenza Vaccination in HIV Shows Benefit and Safety

Prof Marc Mendelson

It's that time of year again, when HIV-infected clients are counseled to have the influenza vaccination. Until the publication of a recent double blind, randomized controlled trial of trivalent influenza vaccine against placebo carried out by Madhi and colleagues in Johannesburg [1], the evidence for benefit from influenza vaccination came mainly from case reports documenting increased influenza complications and longer illness duration.

Madhi's study of 506 HIV-infected adults seen in Themba Lethu Clinic, Johannesburg, randomized patients to receive trivalent influenza vaccine containing H1N1, H3N2 and Influenza B strains, or a placebo control. Patients were either ART-naïve with CD4 count >100 cells/mm³ or established on ART for >3 months. Overall efficacy of the trivalent vaccine against confirmed influenza illness was 75.5%, albeit with wide confidence limits, and seroconversion rates for H1N1, H3N2 and Influenza B was 52.6%, 60.8% and 53.6% respectively. There was no difference between frequency of adverse events in the study and placebo groups, with injection-site tenderness being the commonest finding. Interpretation of safety of the vaccine was limited to relatively healthy HIV-infected patients, as advanced HIV and patients with multiple co-morbidities were under-represented.

However, these results are important in demonstrating safety of influenza vaccination in HIV-infected patients with good efficacy. Seasonal and pandemic influenza is associated with increased hospital admission rates and secondary bacterial infections in HIV-infected patients and despite ART, the risk of severe influenza still outweighs that for the general population. Hence, all clients living with HIV should be offered influenza vaccination. The priority for clients with advanced HIV and/or CD4 counts of <100 cells/mm³ should be to start ART in order to allow immune reconstitution. However, influenza vaccination is not contraindicated for clients with low CD4 counts and although the antibody response may not be optimal, high risk clients such as pregnant women with HIV or HIV-infected patients with chronic lung disease should be vaccinated.

Influenza vaccination should be performed annually as antibody titres wane over the 12 month period, reducing protection.

References

- 1) Madhi et al. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis 2011;52(1):128-37

*This article is reprinted with permission from the Aid for Aids (AfA) Healthcare Professional Newsletter, June 2011: Issue 29. All AfA Healthcare Professional Newsletters are available online at <http://www.aidforaids.co.za>. Past issues can also be downloaded on the Society's website, www.sahivsoc.org, under the **publications** tab.*

Society Publications

HIV NURSING MATTERS

The latest edition of *HIV Nursing Matters* is available on the Society's website, www.sahivsoc.org, under the **publications** tab. Society members are encouraged to submit articles for the Editor's consideration. Articles cannot exceed 1500 words and should be submitted to the editor, Nelouise Geyer, via email: Nelouise@sahivsoc.org.

SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE

The latest edition of the *Journal* can be viewed online at the Society's website, www.sahivsoc.org, or on the Journal's website, www.sajhivmed.org.za.

Article submission: Articles should be submitted to the editor online at www.sajhivmed.org.za. Once an article has been submitted, the author will receive an acknowledgement of receipt, and the article will be subject to a peer review. The authors of all published articles will be awarded 15 CPD points, and co-authors will receive 5 CPD points. Reviewers of published articles will receive 3 CPD points. We are happy to accept articles from people writing for publication for the first time, and will provide support to first-time authors.

TRANSCRIPT

The Society will include resources relevant to clinicians, e.g. information on trainings, events, books, materials or other items, in *Transcript*. Short articles on timely issues are also considered. Please send resource information or article suggestions to Laurie Schowalter at laurie@sahivsoc.org.

Branch Meetings Dates 2011

Please note that the below dates are provisional and may be subject to change. For more information, please contact the relevant branch coordinator.

PROVINCE / CITY	DATE	VENUE	TIME	COORDINATOR CONTACT DETAILS
EASTERN CAPE				
East London	27 September 23 November	Drs du Buisson & Partners, Ampath Laboratory, 58 St James Rd, Southernwood	19:00	Ms Daphne Gernetzky Tel: 043 703 4300 Email: gernetzkyd@ampath.co.za
Mthatha	14 Sept 9 November			Dr Angela Smith Email: dr.angela.smith@gmail.com
Port Elizabeth	25 August 27 October 24 November	The President's Suite, St George's Cricket Ground	19:00	Dr Kas Kasongo Tel: 041 451 4423 Email: kasongo@pathcare.co.za
FREE STATE				
Bloemfontein	TBD	Bloemfontein Medi-Clinic Seminar Room 6th floor	18:30	Madaleen Janse van Vuuren Tel: 051 401 4633 Email: mvanvuuren@pathcare.co.za
Welkom	25 August 24 November			Dr Mandla Mphuthi Email: mandlamphuthi@hotmail.com Dr Ralph Nhiwatiwa Email: drnhiwatiwa2@hotmail.com
GAUTENG				
Johannesburg	25 August 22 September 27 October 24 November	Glenhove Conference Centre, 52 Glenhove Rd, Houghton	19:00	Prof Francois venter Email: fventer@rhru.co.za Rsvp: Ms Natalie Martyn Tel: 079 393 4793 Email: nataliem@afrihost.co.za
Pretoria	4 August 1 September 6 October 3 November	Muelmed Hospital Boardroom, Pretorius St, between Hamilton and Leyds Streets	18:30	Dr Mariette Botes Tel: 012 440 0758 Email: mariette@hivpractice.co.za; Dr Lynne Webber Email: webberl@lancet.co.za Ms Elizabeth Malela Cell: 082 631 1588
KWAZULU NATAL				
Durban	21 September 16 November	TBD		Prof Yunus Moosa – moosay@ukzn.ac.za Ms Sue Anderson – sueand@absamail.co.za Dr Fundisiwe Chonco – choncof@ukzn.ac.za Ms Wendy Dhlomo Mphatswe – Mphatswe@ukzn.ac.za Rsvp Ms Natalie Martyn Tel: 079 393 4793 Email: nataliem@afrihost.co.za
LIMPOPO				
Pietersburg	15 September 17 November	TBD		Dr Sizeka Maweya Email: sizeka@webmail.co.za

MPUMALANGA				
Nelspruit	29 Sept	Nou's Toeka, Nelspruit	18:00	Dr Ebby Mkhabela Tel: (013) 755 1458 Email: ebby.mkhabela@righttocare.org
NORTHERN CAPE				
Northern Cape	31 August 30 November	Various locations		Mr Tsietsi Shushu Tel: 053 343 0011 Cell: 083 993 6976 Email: gtshu@yahoo.com
NORTH WEST PROVINCE				
KOSH (Klerksdorp, Orkney, Stilfontein & Hartebeestfontein)	TBD	Boardroom Klerksdorp Hospital		Ms Tanya Nielson Tel: 018 406 4241 Cell: 083 511 0075 Email: tnielson@auruminstitute.org
Mafikeng	21 September 23 November		18:30	Dr Seli Bogatsu Email: bogatsusele@yahoo.com
WESTERN CAPE				
Cape Town	29 September 24 November	Wolfson Pavilion Lecture Theatre, Institute of Infectious Diseases and Molecular Medicine, UCT Medical School		Dr Graeme Meintjes Email: graemein@mweb.co.za Rsvp: Ms Natalie Martyn Tel: 079 393 4793 Email: nataliem@afrihost.co.za
Paarl	4 August 6 October 1 December	Nelson's Creek Estate	18:30	Dr Dirk Hagemeister Cell: 072 942 6218 Email: Dhagemei@pgwc.gov.za
Garden Route	11 August 6 October 6 December	Geneva Medi-Clinic in George	18:00	Dr Theo van den Handel Cell phone: 083 587 3562 Email: theo.vdhandel@righttocare.org
BOTSWANA				
Gaborone (Southern Branch)	The first Thursday of every month	Boehringer Institute	18:00	Dr Tafireyi Marukutira Email: sahivcs@gmail.com
Francistown (Northern Branch)	Meetings held on the first Wednesday of every month	Conference Room, Nyangabgwe Hospital	19:00	Dr KF Mompoti Tel: (00) 267 713 09897 Cell: (00) 267 241 2518 Dr Samba Nyirenda Tel: (00) 241 5222 ext 216 / 241 7105 Fax (00) 241 4704 Cell (00) 7131 8255
LESOTHO				
Lesotho	TBD	Lehakoe Club (Central Bank of Lesotho)		Dr TG (Prithi) Prithiviraj Cell: (00) 266 6309 7068 Email: prithidel@gmail.com
NAMIBIA				
Windhoek and other centres	TBD			Dr Flavia Mugala-Mukungu Tel: (00) 26 461 246 917 Email: namhivsoc@namibnet.com
ZAMBIA				
Lusaka	Third Wednesday of every other month	Various locations	17:30	Dr Timothy Meade Tel: (+26) 097 865 279 Email: corpmed@zamnet.zm Dr. Mike Bush Tel: (+26) 096 750 999 Email: bush.doctor@zamnet.zm

Ndola	Last Tuesday of every month	Savoy Hotel	18:00	Dr Mulenga Joseph Tel: (+260) 955 889 571 Tel: (+260) 966 780 608 Tel: (+260) 977 572 462 Email: docmulengajo@zamtel.zm
ZIMBABWE				
Harare	To be confirmed			Dr Ingrid Landman tel: (00) 2634 704326 email: sharinghealth@zol.co.zw
Mutare	To be confirmed	Mutare Club	17:30	Dr Munyaradzi Mukuzunga Email: mukuzungam@vaccintrial.africa.ac.zw Email:mmukuzunga@yahoo.com

If you are interested in starting a Branch in your area please contact Fatima Shaik at (+27) 11 341 0162 or fatimas@sahivsoc.org
Please note that branch coordinators are volunteers and do not receive a salary or stipend from the Society.

Branch Meeting Presentations

Branch meeting presentations are available for download on the Society's website homepage (www.sahivsoc.org) in the **presentations** section. Recent posted presentations include an ethics talk by Professor Marc Mendelson, [Transplanting an HIV-infected kidney into an HIV-negative recipient: a step too far or the final piece in the jigsaw?](#), and a talk by Prof Gary Maartens, [Fat redistribution on ARVs: dogma versus data](#).

Emerging Issues Meetings - Johannesburg

The Emerging Issues meetings take place on alternate months, at 18:00, immediately prior to the Johannesburg Branch meeting at the Glenhove Conference Centre. Note that in order to receive CPD points for attendance at **both** the Emerging Issues meeting and the Johannesburg Branch meeting, members must sign both meeting registers. The dates for the remaining 2011 Emerging Issues meetings are **25 August and 27 October**.

Important Information on CPD Points

Branch Meetings

All Society branch meetings held in South Africa are CPD-accredited by SAMA, and health care workers who attend meetings will receive one CPD point for each hour of the presentation. Please note that as of 01 January 2011, CPD points **will only be awarded to Society members whose annual membership fees have been paid in full at the time of the branch meeting**.

We use an automated system for distributing CPD certificates, based on our membership database, so please remember to include your Society membership number on the meeting registers (for your convenience, your membership number will be e-mailed to you with the meeting invitations). If any of your colleagues who are not members of the Society would like to attend the meetings, they are welcome, but please advise that they will not be eligible for CPD points.

Questionnaires

Two points are awarded for the completion of each multiple choice questionnaire in the *Southern African Journal of HIV Medicine*, with a pass rate of 70%. Questionnaires must be submitted online at: <http://www.cpdjournals.co.za/>

If you experience any problems with on-line questionnaire system, please contact Gertrude Fani at: 021 681 7216.

Please note that the Society is no longer able to issue certificates for faxed or posted questionnaires from current or back issues of the Journal.

Authors: Southern African Journal of HIV Medicine

Fifteen CPD points are awarded to the authors of all published articles, and co-authors will receive 5 CPD points. Reviewers of published articles will receive 3 CPD points.

Training Courses

1. COLLEGES OF MEDICINE: DIPLOMA IN HIV MANAGEMENT – DIP HIV MAN (SA):

Examination Structure: Exit Examination: 2 written papers, no oral examination.

Requirements: 6 months supervised training at a teaching or CMSA-approved hospital OR 6 months in an HIV Clinic PLUS 10 day's attendance of HIV Management courses.

For more information on fees, examination dates, syllabus and candidate requirements, please contact the Colleges of Medicine or visit the website:

Tel: 011 726 7037

Website: http://www.collegemedsa.ac.za/view_exam.aspx?examid=59

2. CLINICAL HIV MANAGEMENT COURSE OFFERED BY THE WITS INSTITUTE FOR SEXUAL & REPRODUCTIVE HEALTH, HIV AND RELATED DISEASES

This full time, Johannesburg based two week course includes:

Module 1: Overview - History of HIV to palliative care

Module 2: Basic science

Module 3: TB and other opportunistic infections – prevention, diagnosis and treatment

Module 4: ARVs

Both adult and paediatric treatment and care are covered during the course. Field trips to leading Johannesburg ARV clinics are also part of the 10 day learning experience. 32 CPD points are awarded to participants attending every session and the course provides sound preparation for doctors planning to take the College of Medicine's HIV Management Diploma examination.

Fees are R6 000 or \$US 854.00 for non-South African residents with limited bursaries available.

For further details and application forms visit www.rhru.co.za or contact course co-ordinator Mercy Mopedi: Tel: 011 358 5312 or e-mail: mmopedi@rhru.co.za

Course Date	Closing date for applications
7-18 November 2011	30 September 2011

3. THE TOGA-RIGHT TO CARE MASTERCLASS IN HIV MEDICINE 2011

Time: 08:00 - 10:00

Venue: The Upstairs Boardroom, Toga Laboratory, #7 Meadowdale Office Park, Herman Road, Edenvale, Johannesburg

Coordinator: Dr Dave Spencer, Senior Physician, Toga Laboratory

Contact: Ms Corrien Swanepoel, tel: 011 663-6503

The classes are offered free of charge but space is limited. Those interested in attending should call to reserve a place.

Date	Topic	Speaker
5 August	HIV and the Respiratory Tract. What can we learn?	Mervyn Mer
2 September	HIV and Ethics Part 1: Lessons from Non-disclosure. HIV and Ethics Part 2: Failure to Seek and Remain in Care	Joyce Marshall, Dave Spencer and ethicist Dr Donna Van Bogaert (Wits)
7 October	HIV and Ethics Part 3: Doing HIV Clinical Trial Work in Africa. Are we doing the right thing?	Joyce Marshall, Dave Spencer and ethicist Dr Donna Van Bogaert (Wits)
4 November	HIV in South Africa: Epidemiology. What are the Issues and What is the Future?	Francois Venter (provisional)

4. FOUNDATION FOR PROFESSIONAL DEVELOPMENT COURSES 2011

For more information please contact the Foundation for Professional Development:

Contact person: Stacey Dias
 Tel: (012) 816 9107 or 0861 98 88 98
 E-mail: staceyd@foundation.co.za or foundation@foundation.co.za
 Website: www.foundation.co.za

Course	Points	Dates	City
Clinical Management of HIV/AIDS for Health Care Professionals	30 CEU's (level 2)	16-18 Sept 11-13 Nov	Port Elizabeth Limpopo
HIV/AIDS Refresher Seminar	6 CEU's (level 1)	29 Oct	Mpumalanga
Paediatric HIV/AIDS Management Course	30 CEU's (level 2)	07-09 Oct	Pretoria
HIV/AIDS in the Workplace	30 CEU's (level 2)	08-09 Nov	Pretoria
Integrated Management of TB/STI & HIV	30 CEU's (level 2)	02-04 Sept 02-04 Dec	Kwa-Zulu Natal Pretoria

5. STELLENBOSCH UNIVERSITY NURSING DIVISION: CERTIFICATE IN THE MANAGEMENT OF PATIENTS ON ANTIRETROVIRAL AND TUBERCULOSIS TREATMENT (CMART)

The course consists of a 5 day initial workshop that includes specialized skills training, followed by approximately 20 weeks of clinical practice and distance e-learning. Successful graduates will earn a certificate and have the expertise to assess, diagnose, prescribe medication and manage clients with HIV/AIDS and TB in Primary Health Care.

Who should enrol:

Any registered nurse working in a Primary Health Care facility and who is able to work at clinics or hospitals where there are initiating adults, children and pregnant women on ART.

Course content:

CMART provides the nurse participant with evidence-base clinical management strategies for HIV/AIDS and TB. The course includes training in adult and paediatric care, treatment guidelines and PMTCT.

Admission requirements:

A professional degree or diploma in general nursing
 Current registration with SANC
 Computer literacy and internet access
 Practicing in an ART site or future ART site within which HIV/AIDS and TB management is/will be a service, or able to do practical hours in an ART site to meet logbook requirements

Application process:

Application forms are available: Faculty of Health Sciences, Tygerberg Campus, Nursing Div.
 * Western Cape applicants must apply through the Directorate of Nursing PGWC

6. SCHOOL OF NURSING, UNIVERSITY OF THE FREE STATE 2011 CREDIT BEARING SHORT LEARNING PROGRAMMES

NAME	CREDITS	COST	DURATION	DATE/S
HIV & AIDS Care	36	R2,800.00	6 days	29/09/2011; 13/10/2011; 27/10/2011; 09/11/2011; 10/11/2011; 11/11/2011
INFECTION PREVENTION AND CONTROL	32	R3,900.00	8 days	TO BE ADVISED
WOUND CARE: Diabetic foot ulcers	12	R2,400.00	3 days	03/10/2011 – 05/10/2011
WOUND CARE: Lower leg ulcers	12	R2,400.00	3 days	23/11/2011 – 25/11/2011
AUDIOMETRY	12	R1,900.00	3 days	16/09/2011; 30/09/2011; 07/10/2011
SPIROMETRY	12	R1,900.00	3 days	28/10/2011; 11/11/2011; 25/11/2011

BLOOD TRANSFUSION PRINCIPLES AND PRACTICE	32	R3,990.00	4 days	TO BE ADVISED
STOMA CARE NURSING	12	R3,500.00	3 days	SEPTEMBER 2011
SEXUAL & REPRODUCTIVE HEALTH	32	R3,500.00	5 days	10/08/2011; 24/08/2011; 07/09/2011; 21/09/2011

For further information and application forms please contact:

Diane Keegan

Tel: 051 - 4013629 Fax: 051 – 4013282

E-mail: KeeganD@ufs.ac.za

7. PROBONO.ORG TRAINING WORKSHOP ON HIV AND THE LAW

ProBono.Org is hosting a training workshop for attorneys and other interested stakeholders on various aspects relating to HIV/AIDS and the Law.

When: Friday, 19 August 2011

Time: 09h00 to 12h00

Where: Webber Wentzel, 10 Fricker Road, Illovo Boulevard, Illovo, Johannesburg

RSVP: Kisha (kisha@probono-org.org) by Tuesday, 16 August 2011

Conferences 2011

1. 4TH FIDSSA CONFERENCE

Date: 8 – 11 September 2011

Venue: The Elangeni Hotel, Durban

Website: http://www.fidssa.co.za/B_FIDSSA2011.asp

Contact: Sue McGuinness Communications & Event Management
+27 (0) 11 447 3876 (Tel)
+27 (0) 11 442 8094 (Fax)
clauds.suemc@tiscali.co.za

2. 15TH NATIONAL RURAL HEALTH CONFERENCE

Date: 8 – 10 September 2011

Venue: Rhodes Village, Eastern Cape

Website: <http://www.ruralhealthconference2011.co.za/>

3. INTERNATIONAL CONFERENCE ON PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES

Date: 25-27 September 2011

Venue: Costlands on the Ridge, Durban

Website: http://www.sapharmacol.co.za/CONGRESS_Site/Default.aspx

4. 5TH ANNUAL WORKSHOP ON ADVANCED CLINICAL CARE- AIDS (AWACC)

Date: 6-7 October 2011 (08h00 – 17h00)

Venue: Elangeni, Southern Sun, Hotel, Durban

Registration: To view the programme & register, visit www.mccord.co.za

Cost is R 1000 for two days

Contact: Karen: karen@mccord.co.za /Dr H Sunpath: sunpath@mccord.co.za

Website: www.mccord.co.za

5. 6TH INTERNATIONAL WORKSHOP ON HIV TREATMENT, PATHOGENESIS AND PREVENTION RESEARCH IN RESOURCE-LIMITED SETTINGS

Date: 8 – 11 May 2012

Venue: Mombasa, Kenya

Website: www.virology-education.com

Resources and Services Available

TOLL-FREE NATIONAL HIV & TB HEALTH CARE WORKER HOTLINE

The HIV & TB Health Care Worker Hotline is available to provide assistance to health care workers with HIV- and TB-treatment related questions.

Tel: 0800 212 506 or 021 406 6782

Email: pha-mic@uct.ac.za

Fax: 021 448 0503

Website: www.hivhotline.uct.ac.za

Alternatively, send a **SMS or “Please Call Me” to 071 840 1572**, and someone will call you back.

The hotline operates from **Mondays to Fridays 08h30 – 16h30**.

IMMUNOPAEDIA: A NOVEL ONLINE IMMUNOLOGY LEARNING EXPERIENCE

Visit the award winning, Immunology learning website specifically designed for South African clinicians:

www.immunopaedia.org.za. Immunopaedia aims to integrate and link clinical and immunological aspects of infectious and non-infectious diseases with treatment. The site utilises case studies, unique colour graphics and cutting edge stories from the world of immunology to teach clinicians, paediatricians, researchers, health care workers and students in clinical immunology. This learning environment facilitates an understanding of the immune system and brings together the worlds of clinical decision-making and immunology.

Register on the website today to earn 3 CPD points per case study and to receive a free monthly newsletter.

AFRICAN JOURNAL OF LABORATORY MEDICINE

The African Society for Laboratory Medicine (ASLM), recently established with support from WHO, the African Union, CDC, PEPFAR, World Bank, the Clinton Foundation, UNAIDS and others, is launching a new international peer-reviewed journal, the *African Journal of Laboratory Medicine*. ASLM’s goal is to advance the profession of laboratory medicine in Africa, and the journal will take a broad perspective on the role of laboratory and laboratorians in clinical care and public health efforts. It will provide much-needed communication in the profession of laboratory medicine, and be a forum for laboratories to communicate with other biomedical scientists and clinicians, the medical community, public health officials, and policy makers.

The journal will initially be published quarterly, and will be available with open access online. Articles about the translation of laboratory knowledge, practices, and technologies into clinical care, the interface of laboratory with medical science, laboratory-based epidemiology, and laboratory investigations and evidence-based effectiveness in real world settings are of particular interest. Any articles may be submitted in English or French.

For more information on this inaugural issue or to submit manuscripts, please visit www.afslm.org.

QUACKDOWN!

The Treatment Action Campaign, Community Media Trust and other partners launched a new website to expose quackery and help patients make informed choices about health care. It is called Quackdown!: <http://www.quackdown.info>.

HIV SUPPORT WEBSITE

www.hivsupport.co.za is a website for people living with HIV and AIDS (PLWHA) in South Africa. The purpose is two-fold: to offer an information-portal to South Africans LWHA and to provide a *free* 24/7 online support group for PLWHA, families and supporters. Featured topics will include PMTCT, children with HIV, TB and HIV, state drugs and other locally applicable information. Currently the site provides some basic information, with plans to grow and add the support group within the next couple of months. Please feel free to refer your patients to the website.

BACK ISSUES OF THE SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE

The Society has a limited number of back issues of the *Southern African Journal of HIV Medicine*, available free of charge to members on a first come, first served basis. To order back issues, please contact 011 341 0162 or email: sahivsoc@sahivsoc.org

The Society Guidelines

The Society has published the following guidelines in the *Southern African Journal of HIV Medicine*:

- **Guideline on Safer Conception in Fertile HIV-Infected Individuals and Couples:** Published June 2011 (Issue 40)
- **INH Preventive Therapy (IPT) in HIV Infected South African Children:** Published June 2011 (Issue 40)
- **Management of HIV-Hepatitis B Co-Infection:** Published April 2011 (Issue 39)
- **ARV therapy in Children:** Published December 2009 (Issue 36)
- **Criteria for Expedited ARV Initiation:** Published March 2009 (Issue 33)
- **Post-Exposure Prophylaxis:** Published in November 2008 (Issue 31)
- **Prisoners:** Published in June 2008, with poster (Issue 30)
- **Renal Replacement Therapy:** Published in June 2008 (Issue 30)
- **Adult ART:** Published in April 2008 (Issue 29)
- **Cryptococcal Meningitis:** Published in December 2007, with poster (Issue 28)
- **Displaced Populations:** Published in 2007 (Issue 26)
- **Nutrition:** Chapters 1 & 2 published in June 2007 (Issue 27). Chapters 3 - 6 published in April 2008 (Issue 29)

The above guidelines are available from the Society (contact: 011 341 0162 or e-mail: sahivsoc@sahivsoc.org). They can also be downloaded from the [Society website: www.sahivsoc.org](http://www.sahivsoc.org) or the SA Journal of HIV Medicine website: www.sajhivmed.org.za

The Society would like to thank the following companies, organizations and donors for their financial support in producing the above guidelines: **ATLANTIC PHILANTHROPIES, ASPEN, CIPLA MEDPRO, PFIZER, UNHCR**

Recommended Reading

Handbook of HIV Medicine (2nd Edition) edited by Douglas Wilson, Mark Cotton, Linda-Gail Bekker, Tammy Meyers, Francois Venter, and Gary Maartens, published by Oxford University Press. The second edition of the handbook is now available from Oxford University Press: Tel: 021 5961222, e-mail: orders.za@oup.com or website: <http://www.oxford.co.za>

Aid for AIDS Clinical Guidelines 8th edition 2010/2011 Contributors: Prof. Gary Maartens, Prof. Mark Cotton, Prof. Graeme Meintjes, Prof. Marc Mendelson, Dr. Helena Rabie, AfA Clinical Staff. Editors: Dr. Leon Regensberg, Mrs. Colleen Whitelaw. The guidelines have been thoroughly revised and updated. New sections, including HIV and the Traveller, Infection Control / Prevention and Hepatitis B coinfection, have been added. The section on managing ART and TB drug hepatotoxicity has been expanded. In order to assist practitioners further, a poster-size simplified guide to antiretroviral therapy in adults has been included. To order a free copy, send an email to afa@afadm.co.za with your postal address, or phone AfA on 0860 100 646.

The Clinical Practice of HIV Medicine by Dr David C Spencer. Please note this book is out of print and copies are no longer available. A second edition is planned for publication later this year.

HIV/AIDS in South Africa edited by SS Abdool Karim and Q Abdool Karim, published by Cambridge University Press. This book covers all aspects of HIV/AIDS in SA from epidemiology, prevention strategies, basic science, medicine, sociology, economics, politics and treatment. To order a copy, contact Cambridge University Press: tel: (021) 412 7800, fax: (021) 419 0594, email: orders@cambridge.org or website: www.cambridge.org

Medical Management of HIV Infection (South African Edition) by John G. Bartlett, MD, Joel E. Gallant, MD MPH and Dr FM Conradie, published by TheraSim in cooperation with the Foundation for Professional Development, 2008.

Adult HIV: A learning programme for professionals by the Desmond Tutu HIV Foundation, published by Electric Book Works, 2008. For more information on downloading or ordering a copy, go to: www.EBWhealthcare.com

Primary HIV Clinical Care (5th Ed) by Dr Clive Evian, published by Jacana Media. This is a practical guide for health care personnel in primary care centres. It includes HIV clinical care for adults, children and pregnant women with latest updated national guidelines. To order a copy, contact Jacana Media: tel (011) 628 3200, fax (011) 482 7282, email orders@jacana.co.za or website: www.jacana.co.za

Internet-based Discussion Groups

The Society hosts three internet-based discussion groups which utilise case studies to build the capacity of health care workers to address HIV- and TB-related clinical and ethical questions:

- Paediatric Discussion Group (Manager/Moderator: Dr Leon Levin):**
 To join please send your e-mail address to Dr Leon Levin: leonlevin@54.co.za or subscribe [online](#)
- Adult HIV Discussion Group (Manager/Moderator: Dr Francesca Conradie):**
 To join please send your first name, surname and email address to Dr Francesca Conradie: adghiv@witshealth.co.za
- HIV Policy and Ethics Discussion Group (Manager: Ms Marlise Richter):**
 To join please send your name, surname and e-mail address to Marlise at: ethics.policy@gmail.com
 (To view past debates: <http://groups.google.com/group/policy-ethics?hl=en>)

The latest Antiretroviral (ART) SEP Prices Direct from the Manufacturer

WARNING: additional fees may be incurred when purchasing per prescription, per month, for dispensing and door-to-door delivery from pharmacies. Prices are accurate at time of going to press. Updated prices are available at: www.sahivsoc.org

NAME	STRENGTH	NAPPI CODES	COMPANY	QUANTITY	PRICE
KALETRA SOLUTION		700924	ABBOTT	300ML	R 256.36 INC VAT
NORVIR CAPSULES	100MG	836095014	ABBOTT	84	R 69.41 INC VAT
NORVIR ORAL SOLUTION	80MG/ML	838527035	ABBOTT	90ML	R 59.43 INC VAT
ALUVIA 200/50 TABS	LOP 200MG + RIT 50MG	710028001	ABBOTT	120	R 256.36 INC VAT
ALUVIA 100/25 PED TABS	LOP 100MG + RIT 25MG	715433001	ABBOTT	60	R 64.10 INC VAT
ADCO					
ADCO-ABACAVIR	300MG	715347001	ADCOCK	60	R 590.09 INC VAT
ADCO-EFAVIRENZ	50MG	715585001	ADCOCK	30	R 24.95 INC VAT
ADCO-EFAVIRENZ	200MG	712932001	ADCOCK	90	R 238.26 INC VAT
ADCO-EFAVIRENZ	600MG	709545001	ADCOCK	30	R 144.82 INC VAT
ADCO-LAMIVUDINE	150MG	707962001	ADCOCK	60	R 84.66 INC VAT
ADCO-LAMIVUDINE SOLUTION	10MG/1ML	708708001	ADCOCK	240ML	R 67.39 INC VAT
ADCO-LAMIVUDINE ALCOHOL & SUGAR FREE	10MG/1ML	708713001	ADCOCK	240ML	R 67.39 INC VAT
ADCO-NEVIRAPINE (BLISTER)	200MG	707961001	ADCOCK	60	R 158.95 INC VAT
ADCO-ZIDOVUDINE	300MG	707960001	ADCOCK	60	R 213.68 INC VAT
ADCO-ZIDOVUDINE SYRUP	50MG/5ML	708709001	ADCOCK	200ML	R 71.55 INC VAT
ADCO-ZIDOVUDINE ALCOHOL & SUGAR FREE	50MG/5ML	708711001	ADCOCK	200ML	R 71.55 INC VAT
ASPEN					
ATAZANAVIR CAPSULES	150MG	715828001	ASPEN	60	R 295.20 INC VAT
ATAZANAVIR CAPSULES	200MG	715827001	ASPEN	60	R R364.78 INC VAT
ABACAVIR SOLUTION	20MG/ML	713758001	ASPEN	240ML	R 254.35 INC VAT

ABACAVIR TABS	300MG	715063001	ASPEN	60	R 715.92 INC VAT
DIDANOSINE	25MG	703330001	ASPEN	60	R 116.43 INC VAT
DIDANOSINE	50MG	703332001	ASPEN	60	R 115.07 INC VAT
DIDANOSINE	100MG	703333001	ASPEN	60	R 122.41 INC VAT
DIDANOSINE	150MG	703392001	ASPEN	60	R 171.39 INC VAT
EFAVIRENZ	600MG	710019001	ASPEN	30	R 165.88 INC VAT
LAMIVUDINE	150MG	703716001	ASPEN	60	R 97.86 INC VAT
LAMIVUDINE SYR	10MG/ML	703715001	ASPEN	240ML	R 76.90 INC VAT
LAMZID (AZT+3TC)	AZT 150MG+ 3TC 300MG	703627001	ASPEN	60	R 325.97 INC VAT
NEVIRAPINE	200MG	703718001	ASPEN	60	R 189.54 INC VAT
NEVIRAPINE SUSPENSION	10MG/ML	704731001	ASPEN	240ML	R 129.01 INC VAT
PREZISTA (DARUNAVIR)	300MG	715303001	ASPEN	120	R 977.72 INC VAT
STAVUDINE	15MG	704885001	ASPEN	60	R 33.39 INC VAT
STAVUDINE	20MG	701172001	ASPEN	60	R 37.27 INC VAT
STAVUDINE	30MG	701174001	ASPEN	60	R 42.85 INC VAT
STAVUDINE	40MG	701175001	ASPEN	60	R 47.73 INC VAT
TENOFOVIR	300MG	715056001	ASPEN	30	R 210.90 INC VAT
TENOFOVIR & EMTRICITABINE	TDF 300MG + FTC 150MG	715579001	ASPEN	30	R 313.50 INC VAT
TRUVADA (TDF+FTC)	TDF 300MG + FTC 150MG	708254001	ASPEN	30	R 427.15 INC VAT
VIREAD (TENOFOVIR)	300MG	708253001	ASPEN	30	R 258.05 INC VAT
ZIDOVUDINE	100MG	705452001	ASPEN	100	R 149.99 INC VAT
ZIDOVUDINE	250MG	705455001	ASPEN	60	R 299.63 INC VAT
ZIDOVUDINE	300MG	703712002	ASPEN	60	R 261.84 INC VAT
ZIDOVUDINE SYRUP	50MG/ML	703713001	ASPEN	200ML	R 88.05 INC VAT
VIRTRIUM	D4T 30MG + 3TC 150MG + NVP 200MG	715716001	ASPEN	60	R 284.49 INC VAT
HYDREA CAPSULES	500MG	731706	BMS	100	R 223.97 INC VAT
REYATAZ CAPS	150MG	708257	BMS	60	R 345.50 INC VAT
REYATAZ CAPS	200MG	708258	BMS	60	R 434.72 INC VAT
VIDEX EC CAPS	250MG	704783	BMS	30	R 199.90 INC VAT
VIDEX EC CAPS	400MG	703785	BMS	30	R 257.97 INC VAT
ZERIT CAPSULES	15MG	841315	BMS	60	R 54.36 INC VAT
ZERIT CAPSULES	20MG	837458	BMS	56	R 54.26 INC VAT
ZERIT CAPSULES	30MG	841323	BMS	60	R 54.26 INC VAT
ZERIT CAPSULES	40MG	837407	BMS	60	R 54.26 INC VAT
VIRAMUNE TABLETS	200MG	840645	BOEHRINGER- INGELHEIM	60	R 189.55 INC VAT
VIRAMUNE SYRUP	10MG/ML	861855	BOEHRINGER- INGELHEIM	240ML	R 131.64 INC VAT
CIPLA-ABACAVIR	300MG	714098001	CIPLA	60	R 715.92 INC VAT
CIPLA-ABACAVIR SOLUTION	20MG/ML	714099001	CIPLA	240ML	R 270.80 INC VAT
CIPLA-DIDIVIR	300MG	715091001	CIPLA	30	R 313.50 INC VAT

CIPLA-DUOVIR		707300001	CIPLA	60	R 310.61 INC VAT
CIPLA-DUOVIR & EFAVIRENZ TABLETS CO-PACK	600MG	712993001	CIPLA	30 x tabs 3's	R 379.62 INC VAT
CIPLA-EFAVIRENZ	600MG	709331001	CIPLA	30	R 164.92 INC VAT
CIPLA-LAMIVUDINE TABS	150MG	701282003	CIPLA	60	R 103.08 INC VAT
CIPLA-LAMIVUDINE TABS	300MG	709337001	CIPLA	30	R 96.60 INC VAT
CIPLA-LAMIVUDINE ORAL SOLUTION	50MG/5ML	704041001	CIPLA	100ML	R 31.59 INC VAT
CIPLA-LAMIVUDINE ORAL SOLUTION	50MG/5ML	704041002	CIPLA	240ML	R 75.81 INC VAT
CIPLA-NEVIRAPINE TABS	200MG	704036001	CIPLA	60	R 189.54 INC VAT
CIPLA-NEVIRAPINE ORAL SUSPENSION	50MG/5ML	704040001	CIPLA	240ML	R 122.32 INC VAT
CIPLA-STAVIR 30	30MG	701342001	CIPLA	60	R 39.90 INC CAT
CIPLA-TENOFOVIR	300MG	714097001	CIPLA	30	R 210.90 INC VAT
CIPLA-TRIOMUNE-30		707970001	CIPLA	60	R 284.49 INC VAT
CIPLA-ZIDOVUDINE CAPSULES	100MG	704037001	CIPLA	100	R 173.18 INC VAT
CIPLA-ZIDOVUDINE	100MG	704037002	CIPLA	120	R 207.81 INC VAT
CIPLA-ZIDOVUDINE TABS	300MG	704038001	CIPLA	60	R 275.97 INC VAT
CIPLA-ZIDOVUDINE ORAL SOLUTION	50MG/5ML	704039001	CIPLA	100ML	R 40.25 INC VAT
CIPLA-ZIDOVUDINE ORAL SOLUTION	50MG/5ML	704039002	CIPLA	200ML	R 80.51 INC VAT
3TC TABLETS	150MG	821632019	GSK	60	R 120.48 INC VAT
3TC SOLUTION	50MG/5ML	821640003	GSK	240ML	R 85.51 INC VAT
COMBIVIR (AZT+3TC)	AZT 300MG + 3TC 150MG	875821006	GSK	60	R 365.94 INC VAT
HIV STARTER PACK (AZT+3TC)	AZT 100MG + 3TC 150MG	842346008	GSK	3 DAY KIT	R 53.48 INC VAT
KIVEXA (3TC+ABC)	3TC 300MG + ABC 600MG	707321001	GSK	30	R 922.26 INC VAT
RETROVIR CAPSULES (AZT)	100MG	784265003	GSK	100	R 230.18 INC VAT
RETROVIR CAPSULES (AZT)	250MG	837350026	GSK	60	R 315.88 INC VAT
RETROVIR TABLETS (AZT)	300MG	885317002	GSK	60	R 344.17 INC VAT
RETROVIR IVI	20MG/1ML	825018005	GSK	INF 200MG 5's	R 343.11 INC VAT
RETROVIR SYRUP	50MG/5ML	794236006	GSK	200ML	R 90.05 INC VAT
TELZIR (FOSAMPRENAVIR)	700MG	712478001	GSK	60	R 1481.48 INC VAT
TELZIR SUSPENSION (FOSAMPRENAVIR)	50MG/ML	713582001	GSK	225ML	R 494.89 INC VAT
TRIZIVAR (AZT+3TC+ABC)	AZT 300MG +3TC 150MG +ABC 300MG	703537001	GSK	60	R 1630.03 INC VAT
ZIAGEN (ABC)	300MG	898531003	GSK	60	R 961.67 INC VAT
ZIAGEN SOLUTION (ABC)	100MG/5ML	898538009	GSK	240ML	R 364.22 INC VAT
ATRIPLA TABLETS	EFV 600MG + FTC 200MG + TDF 300MG	715578001	MSD	30	R 483.78 INC VAT
CRIXIVAN CAPSULES	400MG	824445007	MSD	120	R 576.14 INC VAT

ISENTRESS	400MG	715825001	MSD	60	R 878.37 INC VAT
STOCRIN TABLETS	50MG	712069001	MSD	30	R 39.10 INC VAT
STOCRIN TABLETS	200MG	712070001	MSD	90	R 370.42 INC VAT
STOCRIN TABLETS	600 MG	703318001	MSD	30	R 217.67 INC VAT
AURO-ABACAVIR ORAL SOLUTION	20MG/ML	715494001	NOVAGEN PHARMA	240ML	R 254.34 INC VAT
AURO-ABACAVIR TABLETS	300MG	715493001	NOVAGEN PHARMA	60	R 715.91 INC VAT
AURO-EFAVIRENZ	50MG	710592001	NOVAGEN PHARMA	30	R 31.19 INC VAT
AURO-EFAVIRENZ	200MG	710593002	NOVAGEN PHARMA	90	R 297.98 INC VAT
AURO-EFAVIRENZ	600MG	710594001	NOVAGEN PHARMA	30	R 164.93 INC VAT
AURO-LAMIVUDINE	150MG	710602001	NOVAGEN PHARMA	60	R 97.29 INC VAT
AURO-LAMIVUDINE ORAL SOLUTION	10MG/ML	710603001	NOVAGEN PHARMA	240ML	R 75.80 INC VAT
AURO-LAMIZIDO	150MG/300MG	710596001	NOVAGEN PHARMA	60	R 325.70 INC VAT
AURO-NEVIRAPINE	200MG	710606001	NOVAGEN PHARMA	60	R 189.53 INC VAT
AURO-NEVIRAPINE ORAL SUSPENSION	50MG/5ML	710604001	NOVAGEN PHARMA	240ML	R 128.89 INC VAT
AURO-STAVUDINE	30MG	710589001	NOVAGEN PHARMA	60	R 41.31 INC VAT
AURO-STAVUDINE POWDER FOR ORAL SOLUTION	1MG/ML	710591001	NOVAGEN PHARMA	200ML	R 27.44 INC VAT
AURO-ZIDOVUDINE	100MG	710597002	NOVAGEN PHARMA	100	R 186.05 INC VAT
AURO-ZIDOVUDINE	300MG	710600001	NOVAGEN PHARMA	60	R 261.78 INC VAT
AURO-ZIDOVUDINE ORAL SOLUTION	50MG/5ML	710634001	NOVAGEN PHARMA	240ML	R 83.02 INC VAT
AURO-ZEFIN	300MG	715072001	NOVAGEN PHARMA	30	R 219.34 INC VAT
TYRICTEN TABLETS	FTC 200MG + TDF 300MG	715071001	NOVAGEN PHARMA	30	R 313.50 INC VAT
BACTRIM	80MG + 400MG	706434005	ROCHE	20	R 64.79 INC VAT
BACTRIM DS	160MG + 800MG	706442008	ROCHE	10	R 69.17 INC VAT
BACTRIM INFUSION	80MG + 400MG/5ML	706418018	ROCHE	5	R 221.41 INC VAT
VIRA-CEPT POWDER	50MG/G	709826001	ROCHE	144	R 350.31 INC VAT
INVI-RASE CAPSULES	200MG	825697018	ROCHE	270	R 797.18 INC VAT
SONKE ABACAVIR	300MG	715012001	SONKE	60	R 531.24 INC VAT
SONKE ABACLAMIZID	300MG+150MG+300MG	714993011	SONKE	60	R 592.80 INC VAT
SONKE DIDANOSINE	25MG	709870001	SONKE	60	R 89.92 INC VAT
SONKE DIDANOSINE	50MG	709871001	SONKE	60	R 100.55 INC VAT
SONKE DIDANOSINE	100MG	709872001	SONKE	60	R 110.31 INC VAT

SONKE DIDANOSINE	250MG	715670001	SONKE	30	R 159.60 INC VAT
SONKE DIDANOSINE	400MG	715671001	SONKE	30	R 222.30 INC VAT
SONKE EFAVIRENZ	200MG	709529001	SONKE	90	R 207.94 INC VAT
SONKE EFAVIRENZ	600MG	709528001	SONKE	30	R 134.52 INC VAT
SONKE LAMIVUDINE	150MG	703378001	SONKE	60	R 44.40 INC VAT
SONKE LAMI+ZIDO	150MG + 300MG	707971001	SONKE	60	R 250.80 INC VAT
SONKE LAMI NEV STAV	150MG+200MG+ 30MG	709840001	SONKE	60	R 231.19 INC VAT
SONKE NEVIRAPINE	200MG	709533001	SONKE	60	R 171.00 INC VAT
SONKE STAVUDINE	30MG	709530001	SONKE	60	R 34.18 INC VAT
SONKE TENOFOVIR	300MG	714994001	SONKE	60	R 204.06 INC VAT
SONKE ZIDOVUDINE	300MG	709531001	SONKE	60	R 228.00 INC VAT

Disclaimer: The views of the editor and contributors do not necessarily reflect the views of the Southern African HIV Clinicians Society's President, Executive Committee or the Society's members.